Drug Trial Radar · NCT03894046
Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
Last checked: Nov 20, 2026Latest source record: Feb 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
207
Actual
Start
Sep 5, 2019
Primary completion
Jul 26, 2021
Study completion Jul 26, 2021
Sponsor
- Lead sponsor
- Entasis TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 28, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-part study, with Part A being the randomized, controlled portion of the study in patients with ABC hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), or bacteremia. Part B is the single-group portion of the study and includes ABC infections that are resistant to or have failed colistin or polymyxin B treatment, as detailed in the inclusion criteria.
Conditions
- Acinetobacter Baumannii-calcoaceticus Complex
- Hospital-acquired Bacterial Pneumonia
- Ventilator-associated Bacterial Pneumonia
- Bacteremia
- Colistin Resistant ABC
Interventions
SulbactamDrug
1.0 g sulbactam IV infused over 3 hours every 6 hours (q6h).
DurlobactamDrug
1.0 g durlobactam IV infused over 3 hours every 6 hours (q6h). Sulbactam-Durlobactam: Treatment for 7 days up to 14 days if clinically indicated.
ColistinDrug
Treatment for 7 days up to 14 days if clinically indicated.
Imipenem/Cilastatin 500 mg/500 mgDrug
1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h. Treatment for 7 days up to 14 days if clinically indicated.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Patients With All-Cause Mortality in CRABC m-MITT PopulationTime frame: 28 Days
- Proportion of Patients With NephrotoxicityTime frame: 28 days
Locations
90 sites in 17 countries. Site status is shown where the registry gives one.
Entasis Research Site
Chicago, Illinois
Entasis Research Site
Shreveport, Louisiana
Entasis Research Site
Cincinnati, Ohio
Entasis Research Site
Memphis, Tennessee
Entasis Research Site
Houston, Texas
Entasis Research Site
Brest, Belarus
Entasis Research Site
Grodno, Belarus
Entasis Research Site
Homyel, Belarus
Entasis Research Site
Minsk, Belarus
Entasis Research Site
Belo Horizonte, Brazil
Entasis Research Site
Campinas, Brazil
Entasis Research Site
Porto Alegre, Brazil
Entasis Research Site
Salvador, Brazil
Entasis Research Site
São José do Rio Preto, Brazil
Entasis Research Site 1
Beijing, China
Entasis Research Site 2
Beijing, China
Entasis Research Site 3
Beijing, China
Entasis Research Site
Changsha, China
Entasis Research Site
Chongqing, China
Entasis Research Site
Guangzhou, China
Entasis Research Site
Hebei, China
Entasis Research Site 1
Hefei, China
Entasis Research Site 2
Hefei, China
Entasis Research Site
Hubei, China
Entasis Research Site
Nanchang, China
Entasis Research Site
Nanjing, China
Entasis Research Site
Nanning, China
Entasis Research Site 1
Shanghai, China
Entasis Research Site 2
Shanghai, China
Entasis Research Site
Shenzhen, China
Entasis Research Site
Tianjin, China
Entasis Research Site
Wuhan, China
Entasis Research Site 1
Athens, Greece
Entasis Research Site 3
Athens, Greece
Entasis Research Site
Heraklion, Greece
Entasis Research Site
Larissa, Greece
Entasis Research Site
Thessaloniki, Greece
Entasis Research Site 1
Budapest, Hungary
Entasis Research Site 2
Budapest, Hungary
Entasis Research Site
Debrecen, Hungary
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.